{"success":true,"data":{"pressRelease":{"id":"113987","rtpr_id":"nGNXbCgYC6","ticker":"NNOX","exchange":"NASDAQ","all_tickers":["NNOX"],"title":"Nanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO","author":"Globe Newswire","published_at":"2026-08-10T12:10:00.304Z","article_body":"On-premise medical imaging AI framework uses Intel Core Ultra processors and\nIntel’s OpenVINO toolkit to accelerate edge inference within healthcare\nenvironments\n\nPETACH TIKVA, Israel – August 10 – Nanox AI Ltd.\n(https://www.globenewswire.com/Tracker?data=xBtzCRSAtkiewLJDTbaSs8J12VWS5hEs2AvgOQjlfvJ54y_btm8xU_XOJOzSxdgvoxgE7WD6uXp0Z_kkKh-qN_x3TauigJoJ1n4mVZQehNk=),\na subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), today announced the\noptimization of its medical imaging AI application framework for Intel\nCoreUltra processors using Intel’s OpenVINO toolkit. The framework is\ndesigned to support AI applications running on an on-premise edge device\nwithin healthcare facilities, enabling organizations to evaluate and deploy CT\nimaging AI applications while keeping imaging data within their own\ninfrastructure.\n\nNanox.AI solutions analyze routine medical CT scans to help identify patients\nwith findings correlated with chronic conditions in areas including cardiac,\nliver and bone health. By leveraging existing CT imaging workflows, Nanox.AI\naims to help healthcare organizations derive additional clinical value from\nscans that have already been performed and support preventive care management.\n\nThe optimized AI application framework ran inference successfully and\nefficiently on Intel Core Ultra-class hardware using OpenVINO, demonstrating\nits suitability for on-premise AI processing in medical imaging environments.\n\nIntel Core Ultra processors provide a heterogeneous AI architecture with CPU,\nGPU and NPU compute resources, while OpenVINO helps developers optimize and\ndeploy AI workloads across Intel hardware. For healthcare organizations, this\ncombination can support local inference at the edge, help reduce dependence on\ncloud connectivity, and enable deployment models aligned with hospital\ninfrastructure requirements.\n\n“Nanox.AI is focused on helping healthcare organizations deploy advanced\nmedical imaging AI applications efficiently within their existing\ninfrastructure,” said Sharon Saban, General Manager of Nanox.AI. “Our work\nwith Intel demonstrates how optimized edge inference can help bring AI-enabled\nimaging insights closer to the point of care.”\n\n“Healthcare organizations need practical ways to bring AI closer to clinical\nworkflows while supporting performance, responsiveness and local data\ncontrol,” said Alex Flores, General Manager, Health and Life Science, Edge\nComputing GroupGoup, Intel. “Nanox.AI’s optimization work with Intel Core\nUltra processors and Intel’s OpenVINO toolkit shows how edge AI can help\nmedical imaging applications run efficiently on-premise, giving providers a\nscalable path to evaluate and deploy AI-enabled insights within their existing\ninfrastructure.”\n\nNanox.AI’s technology has also been featured in Intel’s partner resources\nas an example of a solution built with Intel technology in Intel’s published\npartner brief\n(https://www.globenewswire.com/Tracker?data=yPfX5jsAH-q0dx1w73Mo8CanhW3C4nN0KlNOEkwUQEUMEKuSQctC6GwEMXOPldLKC8tTCsc-dGfJOth7rRfDxQqnWBkNfgR173WBfGH_iPSGvCCsjsB84WLlTQzHdlwygylsS-N6Pvg_mBc7NKWYwF5ydS5UUHqdDts323A24Q8wtZd8etvOGC0GaWXia89fkvAns8pjt9bbQvnN1aHVZg==).\nFor more information about Nanox.AI and its suite of solutions, visit\nwww.nanox.vision/ai.\n\n©Intel, the Intel logo and other Intel marks are trademarks of Intel\nCorporation or its subsidiaries.\n\n(1 )See intel.com/processor claims: Intel® Core™ Ultra Processors (Series\n3). Performance varies by use, configuration, and other factors. Results may\nvary. Intel does not control or audit third-party data. You should consult\nother sources to evaluate accuracy.\n\nAbout Nanox\n\nNanox (NASDAQ: NNOX) is focused on driving the world’s transition to\npreventive health care by delivering an integrated, end-to-end medical imaging\nand healthcare services platform.\n\nNanox combines affordable imaging hardware, advanced AI-based solutions,\ncloud-based software, access to remote radiology, health IT solutions, and a\nmarketplace to enable earlier detection, improved clinical efficiency, and\nbroader access to care.\n\nNanox’s vision is to expand the reach of medical imaging both within and\nbeyond traditional hospital settings by providing a seamless solution from\nscan to interpretation and beyond. By leveraging proprietary digital X-ray\ntechnology, AI-driven analytics, and a clinically driven approach, Nanox aims\nto enhance the efficiency of routine imaging workflows, support early\ndetection of disease, and improve patient outcomes.\n\nThe Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source\ndigital tomosynthesis imaging system designed for ease of use and scalability;\nNanox.AI, a suite of AI-based algorithms that augment the interpretation of\nroutine CT imaging to identify early signs often associated with chronic\ndisease; Nanox.CLOUD, a cloud-based platform for secure data management,\nstorage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD\nHoldings, which provides access to remote radiology and cardiology experts and\ncomprehensive teleradiology services; and Nanox Health IT combines deep\nhealthcare IT expertise with leading technology partners to deliver RIS, PACS,\nAI, dictation, and secure infrastructure solutions that streamline workflows\nand support safer, more efficient care delivery.\n\nBy integrating imaging technology, AI, cloud infrastructure, clinical\nexpertise, a marketplace, and health information technology, Nanox seeks to\nlower barriers to adoption, improve utilization, and advance preventive care\nworldwide. For more information, please visit https://www.nanox.vision.\n\nAbout Nanox.AI\n\nNanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox.\nNanox.AI solutions are developed to target highly prevalent chronic and acute\ndiseases affecting large populations around the world. Leveraging AI, Nanox.AI\nhelps clinicians extract valuable and actionable clinical insights from\nmedical imaging that otherwise may go unnoticed, potentially initiating\nfurther medical assessment to establish individual preventative care pathways\nfor patients. For more information, please visit www.nanox.vision/ai.\n\nForward-Looking Statements\n\nThis press release may contain forward-looking statements that are subject to\nrisks and uncertainties. All statements that are not historical facts\ncontained in this press release are forward-looking statements. Such\nstatements include, but are not limited to, statements regarding: the\nCompany’s expected commercialization efforts, business strategy and\nlong-term growth opportunities; the expected timing, pace, extent and success\nof deployments, installations, activations and utilization of Nanox.ARC\nsystems, including under the Nanox Imaging Network; the anticipated benefits,\ntiming and extent of activity under existing commercial, distribution and\nstrategic agreements, including contemplated deployments of hundreds of\nsystems over the coming years; the potential outcome, scope and timing of the\nevaluation of strategic alternatives relating to the Company’s South Korea\noperations, including an expanded restructuring, a potential sale, wind-down\nor closure of all or part of such operations; the initiation, timing, progress\nand results of the Company’s research and development, manufacturing, and\ncommercialization activities with respect to its X-ray source technology and\nthe Nanox.ARC, the ability to realize the expected benefits of its recent\nacquisitions and the projected business prospects of the Company and the\nacquired companies. In some cases, you can identify forward-looking statements\nby terminology such as “can,” “might,” “believe,” “may,”\n“estimate,” “continue,” “anticipate,” “intend,” “should,”\n“plan,” “should,” “could,” “expect,” “predict,”\n“potential,” or the negative of these terms or other similar expressions.\nForward-looking statements are based on information the Company has when those\nstatements are made or management’s good faith belief as of that time with\nrespect to future events and are subject to risks and uncertainties that could\ncause actual performance or results to differ materially from those expressed\nin or suggested by the forward-looking statements. Factors that could cause\nactual results to differ materially from those currently anticipated include:\nrisks related to (i) Nanox’s ability to complete development of the Nanox\nSystem; (ii) Nanox’s ability to successfully demonstrate the feasibility of\nits technology for commercial applications; (iii) Nanox’s history of\nrecurring losses and negative cash flows from operating activities,\nsignificant future commitments and the uncertainty regarding the adequacy of\nNanox’s liquidity to pursue its complete business objectives, and\nsubstantial doubt regarding its ability to continue as a going concern; (iv)\nNanox’s expectations regarding the necessity of, timing of filing for, and\nreceipt and maintenance of, regulatory clearances or approvals regarding its\ntechnology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide\nand its ongoing compliance with applicable quality standards and regulatory\nrequirements; (v) Nanox’s ability to realize the anticipated benefits of the\nacquisitions, which may be affected by, among other things, competition, brand\nrecognition, the ability of the acquired companies to grow and manage growth\nprofitably and retain their key employees; (vi) Nanox’s ability to enter\ninto and maintain commercially reasonable arrangements with third-party\nmanufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market\nacceptance of the Nanox System and the proposed pay-per-scan business model;\n(viii) Nanox’s expectations regarding collaborations with third-parties and\ntheir potential benefits; (ix) Nanox’s ability to conduct business globally;\n(x) changes in global, political, economic, business, competitive, market and\nregulatory forces; (xi) risks related to the current war between Israel and\nHamas and any worsening of the situation in Israel; and (xii) risks related to\nlitigation which may result in significant liability and damage to the\nCompany’s reputation. For a discussion of other risks and uncertainties, and\nother important factors, any of which could cause Nanox’s actual results to\ndiffer from those contained in the Forward-Looking Statements, see the section\ntitled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year\nended December 31, 2025, and subsequent filings with the U.S. Securities and\nExchange Commission. The reader should not place undue reliance on any\nforward-looking statements included in this press release. Except as required\nby law, Nanox undertakes no obligation to update publicly any forward-looking\nstatements after the date of this press release to conform these statements to\nactual results or to changes in the Company’s expectations.\n\nContacts\n\nMedia Contact:\nBen Shannon\nICR Healthcare\nNanoxPR@icrinc.com\n\nInvestor Contact:\nMike Cavanaugh\nICR Healthcare\nmike.cavanaugh@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7a1764f8-84e3-4b28-ae23-9add5d57c378)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbCgYC6","title":"Nanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO","author":"Globe Newswire","ticker":"NNOX","created":"2026-08-10T12:10:00.304Z","tickers":["NNOX"],"exchange":"NASDAQ","article_body":"On-premise medical imaging AI framework uses Intel Core Ultra processors and\nIntel’s OpenVINO toolkit to accelerate edge inference within healthcare\nenvironments\n\nPETACH TIKVA, Israel – August 10 – Nanox AI Ltd.\n(https://www.globenewswire.com/Tracker?data=xBtzCRSAtkiewLJDTbaSs8J12VWS5hEs2AvgOQjlfvJ54y_btm8xU_XOJOzSxdgvoxgE7WD6uXp0Z_kkKh-qN_x3TauigJoJ1n4mVZQehNk=),\na subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), today announced the\noptimization of its medical imaging AI application framework for Intel\nCoreUltra processors using Intel’s OpenVINO toolkit. The framework is\ndesigned to support AI applications running on an on-premise edge device\nwithin healthcare facilities, enabling organizations to evaluate and deploy CT\nimaging AI applications while keeping imaging data within their own\ninfrastructure.\n\nNanox.AI solutions analyze routine medical CT scans to help identify patients\nwith findings correlated with chronic conditions in areas including cardiac,\nliver and bone health. By leveraging existing CT imaging workflows, Nanox.AI\naims to help healthcare organizations derive additional clinical value from\nscans that have already been performed and support preventive care management.\n\nThe optimized AI application framework ran inference successfully and\nefficiently on Intel Core Ultra-class hardware using OpenVINO, demonstrating\nits suitability for on-premise AI processing in medical imaging environments.\n\nIntel Core Ultra processors provide a heterogeneous AI architecture with CPU,\nGPU and NPU compute resources, while OpenVINO helps developers optimize and\ndeploy AI workloads across Intel hardware. For healthcare organizations, this\ncombination can support local inference at the edge, help reduce dependence on\ncloud connectivity, and enable deployment models aligned with hospital\ninfrastructure requirements.\n\n“Nanox.AI is focused on helping healthcare organizations deploy advanced\nmedical imaging AI applications efficiently within their existing\ninfrastructure,” said Sharon Saban, General Manager of Nanox.AI. “Our work\nwith Intel demonstrates how optimized edge inference can help bring AI-enabled\nimaging insights closer to the point of care.”\n\n“Healthcare organizations need practical ways to bring AI closer to clinical\nworkflows while supporting performance, responsiveness and local data\ncontrol,” said Alex Flores, General Manager, Health and Life Science, Edge\nComputing GroupGoup, Intel. “Nanox.AI’s optimization work with Intel Core\nUltra processors and Intel’s OpenVINO toolkit shows how edge AI can help\nmedical imaging applications run efficiently on-premise, giving providers a\nscalable path to evaluate and deploy AI-enabled insights within their existing\ninfrastructure.”\n\nNanox.AI’s technology has also been featured in Intel’s partner resources\nas an example of a solution built with Intel technology in Intel’s published\npartner brief\n(https://www.globenewswire.com/Tracker?data=yPfX5jsAH-q0dx1w73Mo8CanhW3C4nN0KlNOEkwUQEUMEKuSQctC6GwEMXOPldLKC8tTCsc-dGfJOth7rRfDxQqnWBkNfgR173WBfGH_iPSGvCCsjsB84WLlTQzHdlwygylsS-N6Pvg_mBc7NKWYwF5ydS5UUHqdDts323A24Q8wtZd8etvOGC0GaWXia89fkvAns8pjt9bbQvnN1aHVZg==).\nFor more information about Nanox.AI and its suite of solutions, visit\nwww.nanox.vision/ai.\n\n©Intel, the Intel logo and other Intel marks are trademarks of Intel\nCorporation or its subsidiaries.\n\n(1 )See intel.com/processor claims: Intel® Core™ Ultra Processors (Series\n3). Performance varies by use, configuration, and other factors. Results may\nvary. Intel does not control or audit third-party data. You should consult\nother sources to evaluate accuracy.\n\nAbout Nanox\n\nNanox (NASDAQ: NNOX) is focused on driving the world’s transition to\npreventive health care by delivering an integrated, end-to-end medical imaging\nand healthcare services platform.\n\nNanox combines affordable imaging hardware, advanced AI-based solutions,\ncloud-based software, access to remote radiology, health IT solutions, and a\nmarketplace to enable earlier detection, improved clinical efficiency, and\nbroader access to care.\n\nNanox’s vision is to expand the reach of medical imaging both within and\nbeyond traditional hospital settings by providing a seamless solution from\nscan to interpretation and beyond. By leveraging proprietary digital X-ray\ntechnology, AI-driven analytics, and a clinically driven approach, Nanox aims\nto enhance the efficiency of routine imaging workflows, support early\ndetection of disease, and improve patient outcomes.\n\nThe Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source\ndigital tomosynthesis imaging system designed for ease of use and scalability;\nNanox.AI, a suite of AI-based algorithms that augment the interpretation of\nroutine CT imaging to identify early signs often associated with chronic\ndisease; Nanox.CLOUD, a cloud-based platform for secure data management,\nstorage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD\nHoldings, which provides access to remote radiology and cardiology experts and\ncomprehensive teleradiology services; and Nanox Health IT combines deep\nhealthcare IT expertise with leading technology partners to deliver RIS, PACS,\nAI, dictation, and secure infrastructure solutions that streamline workflows\nand support safer, more efficient care delivery.\n\nBy integrating imaging technology, AI, cloud infrastructure, clinical\nexpertise, a marketplace, and health information technology, Nanox seeks to\nlower barriers to adoption, improve utilization, and advance preventive care\nworldwide. For more information, please visit https://www.nanox.vision.\n\nAbout Nanox.AI\n\nNanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox.\nNanox.AI solutions are developed to target highly prevalent chronic and acute\ndiseases affecting large populations around the world. Leveraging AI, Nanox.AI\nhelps clinicians extract valuable and actionable clinical insights from\nmedical imaging that otherwise may go unnoticed, potentially initiating\nfurther medical assessment to establish individual preventative care pathways\nfor patients. For more information, please visit www.nanox.vision/ai.\n\nForward-Looking Statements\n\nThis press release may contain forward-looking statements that are subject to\nrisks and uncertainties. All statements that are not historical facts\ncontained in this press release are forward-looking statements. Such\nstatements include, but are not limited to, statements regarding: the\nCompany’s expected commercialization efforts, business strategy and\nlong-term growth opportunities; the expected timing, pace, extent and success\nof deployments, installations, activations and utilization of Nanox.ARC\nsystems, including under the Nanox Imaging Network; the anticipated benefits,\ntiming and extent of activity under existing commercial, distribution and\nstrategic agreements, including contemplated deployments of hundreds of\nsystems over the coming years; the potential outcome, scope and timing of the\nevaluation of strategic alternatives relating to the Company’s South Korea\noperations, including an expanded restructuring, a potential sale, wind-down\nor closure of all or part of such operations; the initiation, timing, progress\nand results of the Company’s research and development, manufacturing, and\ncommercialization activities with respect to its X-ray source technology and\nthe Nanox.ARC, the ability to realize the expected benefits of its recent\nacquisitions and the projected business prospects of the Company and the\nacquired companies. In some cases, you can identify forward-looking statements\nby terminology such as “can,” “might,” “believe,” “may,”\n“estimate,” “continue,” “anticipate,” “intend,” “should,”\n“plan,” “should,” “could,” “expect,” “predict,”\n“potential,” or the negative of these terms or other similar expressions.\nForward-looking statements are based on information the Company has when those\nstatements are made or management’s good faith belief as of that time with\nrespect to future events and are subject to risks and uncertainties that could\ncause actual performance or results to differ materially from those expressed\nin or suggested by the forward-looking statements. Factors that could cause\nactual results to differ materially from those currently anticipated include:\nrisks related to (i) Nanox’s ability to complete development of the Nanox\nSystem; (ii) Nanox’s ability to successfully demonstrate the feasibility of\nits technology for commercial applications; (iii) Nanox’s history of\nrecurring losses and negative cash flows from operating activities,\nsignificant future commitments and the uncertainty regarding the adequacy of\nNanox’s liquidity to pursue its complete business objectives, and\nsubstantial doubt regarding its ability to continue as a going concern; (iv)\nNanox’s expectations regarding the necessity of, timing of filing for, and\nreceipt and maintenance of, regulatory clearances or approvals regarding its\ntechnology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide\nand its ongoing compliance with applicable quality standards and regulatory\nrequirements; (v) Nanox’s ability to realize the anticipated benefits of the\nacquisitions, which may be affected by, among other things, competition, brand\nrecognition, the ability of the acquired companies to grow and manage growth\nprofitably and retain their key employees; (vi) Nanox’s ability to enter\ninto and maintain commercially reasonable arrangements with third-party\nmanufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market\nacceptance of the Nanox System and the proposed pay-per-scan business model;\n(viii) Nanox’s expectations regarding collaborations with third-parties and\ntheir potential benefits; (ix) Nanox’s ability to conduct business globally;\n(x) changes in global, political, economic, business, competitive, market and\nregulatory forces; (xi) risks related to the current war between Israel and\nHamas and any worsening of the situation in Israel; and (xii) risks related to\nlitigation which may result in significant liability and damage to the\nCompany’s reputation. For a discussion of other risks and uncertainties, and\nother important factors, any of which could cause Nanox’s actual results to\ndiffer from those contained in the Forward-Looking Statements, see the section\ntitled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year\nended December 31, 2025, and subsequent filings with the U.S. Securities and\nExchange Commission. The reader should not place undue reliance on any\nforward-looking statements included in this press release. Except as required\nby law, Nanox undertakes no obligation to update publicly any forward-looking\nstatements after the date of this press release to conform these statements to\nactual results or to changes in the Company’s expectations.\n\nContacts\n\nMedia Contact:\nBen Shannon\nICR Healthcare\nNanoxPR@icrinc.com\n\nInvestor Contact:\nMike Cavanaugh\nICR Healthcare\nmike.cavanaugh@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7a1764f8-84e3-4b28-ae23-9add5d57c378)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-10T12:10:00.373397591Z","server_sent_at_ms":1786363800373},"received_at":"2026-08-10T12:10:00.425Z","source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341807/0/en/nanox-ai-optimizes-medical-imaging-ai-application-framework-for-intel-core-ultra-processors-with-openvino.html"},"analysis":{"id":"102988","press_release_id":"113987","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Substantial doubt regarding ability to continue as a going concern","History of recurring losses and negative cash flows from operating activities","Risks related to war in Israel and Hamas"],"eventType":"operations_update","narrative":"Nanox.AI optimized its medical imaging AI application framework for Intel Core Ultra processors using the OpenVINO toolkit, enabling efficient on-premise edge inference for healthcare facilities.\n\nThis optimization allows healthcare organizations to deploy CT imaging AI applications locally, keeping data within their own infrastructure while leveraging existing imaging workflows.\n\nThe successful demonstration on Intel hardware highlights a scalable path to bring AI-enabled imaging insights closer to the point of care without relying solely on cloud connectivity.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Intel integration unlocks on-premise AI processing for medical imaging."},"keyFigures":{},"quotedText":"Nanox.AI is focused on helping healthcare organizations deploy advanced medical imaging AI applications efficiently within their existing infrastructure","namedEntities":{"people":[{"name":"Sharon Saban","role":"General Manager of Nanox.AI"},{"name":"Alex Flores","role":"General Manager, Health and Life Science, Edge Computing Group, Intel"}],"products":["Intel Core Ultra processors","Intel OpenVINO toolkit","Nanox.ARC","Nanox.CLOUD","Nanox.MARKETPLACE","USARAD Holdings","Nanox Health IT"],"companies":[{"name":"Nanox AI Ltd.","relationship":"subsidiary"},{"name":"Nano-X Imaging Ltd.","ticker":"NNOX","relationship":"parent company"},{"name":"Intel Corporation","ticker":"INTC","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Technical optimization of the AI framework for Intel Core Ultra processors using OpenVINO. While this improves edge deployment capabilities and data privacy, it is a product enhancement rather than a commercial contract, regulatory approval, or financial event."},"tickerRelevance":{"others":[{"ticker":"INTC","relevance":"partner"}],"primary":"NNOX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":["product_launch"],"importanceComponents":{"partner":"Intel","tickerTier":"small-cap","eventGravity":"technical-optimization"}},"event_type":"operations_update","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":2,"narrative":"Nanox.AI optimized its medical imaging AI application framework for Intel Core Ultra processors using the OpenVINO toolkit, enabling efficient on-premise edge inference for healthcare facilities.\n\nThis optimization allows healthcare organizations to deploy CT imaging AI applications locally, keeping data within their own infrastructure while leveraging existing imaging workflows.\n\nThe successful demonstration on Intel hardware highlights a scalable path to bring AI-enabled imaging insights closer to the point of care without relying solely on cloud connectivity.","key_figures":{},"named_entities":{"people":[{"name":"Sharon Saban","role":"General Manager of Nanox.AI"},{"name":"Alex Flores","role":"General Manager, Health and Life Science, Edge Computing Group, Intel"}],"products":["Intel Core Ultra processors","Intel OpenVINO toolkit","Nanox.ARC","Nanox.CLOUD","Nanox.MARKETPLACE","USARAD Holdings","Nanox Health IT"],"companies":[{"name":"Nanox AI Ltd.","relationship":"subsidiary"},{"name":"Nano-X Imaging Ltd.","ticker":"NNOX","relationship":"parent company"},{"name":"Intel Corporation","ticker":"INTC","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T16:14:43.661Z","global_importance":10,"audience_relevance":15,"importance_components":{"partner":"Intel","tickerTier":"small-cap","eventGravity":"technical-optimization"}},"durationMs":102435,"modelName":"glm-4.7"}}